NCT04492891View on ClinicalTrials.gov

Cyclosporine For The Treatment Of COVID-19(+)

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

December 10, 2021

Conditions
SARS (Disease)
Interventions
DRUG

Cyclosporine

2.5 mg/kg PO BID 7 days

OTHER

Standard of Care Treatment

Standard of Care Treatment, N= 25 Patients, 7 days

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Bryan Burt, MD

OTHER

NCT04492891 - Cyclosporine For The Treatment Of COVID-19(+) | Biotech Hunter | Biotech Hunter